FGFR3 and ras mutations in multiple myeloma cell lines
| . | Line . | t(4;14) . | FGFR3 . | FGFR3 cd mut . | nt Change . | N,K-ras cd mut . | nt Change . |
|---|---|---|---|---|---|---|---|
| 1 | UTMC2 | + | + | No | − | No | − |
| 2 | LP1 | + | + | F384L | TTC > CTC | No | − |
| 3 | KMS11 | + | + | Y373C | TAT > TGT | No | − |
| 4 | MM5.1/2 | + | + | Δ* | deletion | No | − |
| 5a | OPM2 | + | + | K650E | AAG > GAG | No | − |
| 5b | OPM1 | + | + | K650E | AAG > GAG | K71 − Q >* | CAG > TAG |
| 6 | H929 | + | + | No | − | N13 − G > D | GGT > GAT |
| 7 | JIM3 | + | − | No | − | K12 − G > D | GGT > GAT |
| 8 | KHM11 | + | + | No | − | N61 − Q > K | CAA > AAA |
| 9 | Karpas1272 | + | + | No | − | K61 − Q > H | CAA > CAC |
| 10 | 8226 | − | − | ND | − | K12 − G > A | GGT > GCT |
| 11 | ARK | − | − | ND | − | N61 − Q > R | CAA > CGA |
| 12 | EJM | − | − | ND | − | K12 − G > A | GGT > GCT |
| 13 | Karpas620 | − | − | ND | − | K12 − G > D | GGT > GAT |
| 14 | KMM1 | − | − | ND | − | N13 − G > D | GGT > GAT |
| 15 | L363 | − | − | ND | − | N61 − Q > H | CAA > CAC |
| 16 | MM1.144 | − | − | ND | − | K12 − G > A | GGT > GCT |
| 17 | MM.S1 | − | − | ND | − | N12 − G > D | GGT > GAT |
| 18 | SKMM1 | − | − | ND | − | N12 − G > D | GGT > GAT |
| 19 | DELTA 47 | − | − | ND | − | No | − |
| 20 | FLAM 76 | − | − | ND | − | No | − |
| 21 | FR4 | − | − | ND | − | No | − |
| 22 | H1112 | − | − | ND | − | No | − |
| 23 | JJN3 | − | − | ND | − | No | − |
| 24 | KMS12 | − | − | ND | − | No | − |
| 25 | ANBL6 | − | − | ND | − | No | − |
| 26 | OCI-MY5 | − | − | ND | − | No | − |
| 27 | PE1 | − | − | ND | − | No | − |
| 28 | SKMM2 | − | − | ND | − | No | − |
| 29 | TH | − | − | ND | − | No | − |
| 30 | U266 | − | − | ND | − | No | − |
| . | Line . | t(4;14) . | FGFR3 . | FGFR3 cd mut . | nt Change . | N,K-ras cd mut . | nt Change . |
|---|---|---|---|---|---|---|---|
| 1 | UTMC2 | + | + | No | − | No | − |
| 2 | LP1 | + | + | F384L | TTC > CTC | No | − |
| 3 | KMS11 | + | + | Y373C | TAT > TGT | No | − |
| 4 | MM5.1/2 | + | + | Δ* | deletion | No | − |
| 5a | OPM2 | + | + | K650E | AAG > GAG | No | − |
| 5b | OPM1 | + | + | K650E | AAG > GAG | K71 − Q >* | CAG > TAG |
| 6 | H929 | + | + | No | − | N13 − G > D | GGT > GAT |
| 7 | JIM3 | + | − | No | − | K12 − G > D | GGT > GAT |
| 8 | KHM11 | + | + | No | − | N61 − Q > K | CAA > AAA |
| 9 | Karpas1272 | + | + | No | − | K61 − Q > H | CAA > CAC |
| 10 | 8226 | − | − | ND | − | K12 − G > A | GGT > GCT |
| 11 | ARK | − | − | ND | − | N61 − Q > R | CAA > CGA |
| 12 | EJM | − | − | ND | − | K12 − G > A | GGT > GCT |
| 13 | Karpas620 | − | − | ND | − | K12 − G > D | GGT > GAT |
| 14 | KMM1 | − | − | ND | − | N13 − G > D | GGT > GAT |
| 15 | L363 | − | − | ND | − | N61 − Q > H | CAA > CAC |
| 16 | MM1.144 | − | − | ND | − | K12 − G > A | GGT > GCT |
| 17 | MM.S1 | − | − | ND | − | N12 − G > D | GGT > GAT |
| 18 | SKMM1 | − | − | ND | − | N12 − G > D | GGT > GAT |
| 19 | DELTA 47 | − | − | ND | − | No | − |
| 20 | FLAM 76 | − | − | ND | − | No | − |
| 21 | FR4 | − | − | ND | − | No | − |
| 22 | H1112 | − | − | ND | − | No | − |
| 23 | JJN3 | − | − | ND | − | No | − |
| 24 | KMS12 | − | − | ND | − | No | − |
| 25 | ANBL6 | − | − | ND | − | No | − |
| 26 | OCI-MY5 | − | − | ND | − | No | − |
| 27 | PE1 | − | − | ND | − | No | − |
| 28 | SKMM2 | − | − | ND | − | No | − |
| 29 | TH | − | − | ND | − | No | − |
| 30 | U266 | − | − | ND | − | No | − |
MM indicates multiple myeloma; *, stop codon; Δ*, deletion of the stop codon; ND, not determined.
At the top of the table are listed the MM cell lines (1-9) that have a t(4;14) translocation and therefore express FGFR3. JIM3 does not express FGFR3, but the original tumor sample from which the cell line was derived does.4 At the bottom of the table are shown the MM lines (10-30) that do not have a t(4;14) translocation and therefore do not express FGFR3. Shaded are the activating mutations in FGFR3 or N,K-ras. Note that the F384L FGFR3 mutation in LP1 and the K71 Ras mutation in OPM1 are not activating (and are not shaded).